0001104659-17-061575.txt : 20171010
0001104659-17-061575.hdr.sgml : 20171010
20171010162255
ACCESSION NUMBER: 0001104659-17-061575
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171010
FILED AS OF DATE: 20171010
DATE AS OF CHANGE: 20171010
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PFIZER INC
CENTRAL INDEX KEY: 0000078003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 171130737
BUSINESS ADDRESS:
STREET 1: 235 E 42ND ST
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 2125732323
MAIL ADDRESS:
STREET 1: 235 E 42ND ST
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER NAME:
FORMER CONFORMED NAME: PFIZER CHARLES & CO INC
DATE OF NAME CHANGE: 19710908
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 BOYLSTON STREET
STREET 2: 11TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 500 BOYLSTON STREET
STREET 2: 11TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
a4.xml
4
X0306
4
2017-10-10
1
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0000078003
PFIZER INC
235 EAST 42ND STREET
NEW YORK
NY
10017
0
0
1
0
Common Stock
2017-10-10
4
C
0
447514
A
447514
D
Common Stock
2017-10-10
4
C
0
940125
A
1387639
D
Common Stock
2017-10-10
4
P
0
40000
17.00
A
1427639
D
Series A Convertible Preferred Stock
2017-10-10
4
C
0
447514
0
D
Common Stock
447514
0
D
Series A-1 Junior Preferred Stock
2017-10-10
4
C
0
940125
0
D
Common Stock
940125
0
D
In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date.
Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis.
/s/ Susan Grant, Assistant Secretary on behalf of Pfizer Inc.
2017-10-10